The new Accelerating Rare Disease Cures program at the US Food and Drug Administration may be as much about relieving external pressure to make a more drastic reorganization than about coordinating rare disease activities.
The ARC program, which rests in the Center for Drug Evaluation and Research, is intended to speed development of rare disease treatments and coordinate all work that could affect rare disease development, such
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?